Schweiz
Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
14 Dezember, 2008
Independent studies validate the utility of Theros BCISM for improving risk stratification of early stage breast cancer patients.
bioMérieux to Develop New Highly-Specific, Non-invasive Test for Prostate Cancer, Reducing Unnecessary Biopsies
25 September, 2008
Prostate cancer is the most prevalent cancer in the United States and the 4th most common worldwide. The combination of a test for a new prostate cancer biomarker, Annexin 3, with the standard screening methods could potentially reduce the number of biopsies conducted by up to 75%, when compared with current screening methods alone.
bioMérieux Gains Critical Oncology and Theranostics Capabilities with the Acquisition of Molecular Diagnostics Company AviaraDx
11 September, 2008
bioMérieux, a world leader in the field of in vitro diagnostics has acquired the privately held AviaraDx, Inc., a molecular in vitro diagnostics company, based in San Diego, California (USA). AviaraDx’s diagnostic tests, based on their proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in making critical therapeutic decisions. The company has built a molecular R&D lab and a small sales & marketing team, as well as a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified service lab.
bioMérieux Delivers New Clean Room Range for Sterility Testing
01 September, 2008
bioMérieux Increases its Lead in Microbiology with the Acquisition of the Swedish Diagnostics Specialist AB BIODISK. Company’s Etest® will enhance bioMérieux’s high medical-value offer.
18 Juni, 2008
bioMérieux, a world leader in the field of in vitro diagnostics has concluded an agreement to acquire the privately held AB BIODISK, a Swedish in vitro diagnostics company with facilities for research and development, manufacturing and marketing located in Stockholm. This is bioMérieux’s fourth acquisition in under two years.
